PE20141469A1 - Inhibidores de la activacion de las celulas t - Google Patents
Inhibidores de la activacion de las celulas tInfo
- Publication number
- PE20141469A1 PE20141469A1 PE2013002910A PE2013002910A PE20141469A1 PE 20141469 A1 PE20141469 A1 PE 20141469A1 PE 2013002910 A PE2013002910 A PE 2013002910A PE 2013002910 A PE2013002910 A PE 2013002910A PE 20141469 A1 PE20141469 A1 PE 20141469A1
- Authority
- PE
- Peru
- Prior art keywords
- ctla
- inhibitors
- specific
- cell activation
- refers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
Abstract
SE REFIERE A UN AGENTE BIOLOGICO BIESPECIFICO QUE COMPRENDE UN LIGANDO ESPECIFICO PARA CTLA-4, QUE SE SELECCIONA DE UN ANTICUERPO ESPECIFICO PARA CTLA-4, Y CD80(B7-1), CD86(B7-2); Y UN LIGANDO ESPECIFICO PARA UN COMPLEJO pMHC, QUE SE SELECCIONA DE UN ANTICUERPO ANTI-MHC Y LAG-3. DICHO LIGANDO ESPECIFICO PARA CTLA-4 ES CD80 QUE COMPRENDE AL MENOS UNA DE LAS MUTACIONES W84A, K71G, K71V, ENTRE OTROS. SE REFIERE TAMBIEN A UN METODO PARA INDUCIR TOLERANCIA DE UNA CELULA T A UN ANTIGENO, SIENDO UTIL PARA EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161503282P | 2011-06-30 | 2011-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141469A1 true PE20141469A1 (es) | 2014-10-31 |
Family
ID=47424568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002910A PE20141469A1 (es) | 2011-06-30 | 2012-06-29 | Inhibidores de la activacion de las celulas t |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US9834604B2 (es) |
| EP (2) | EP2726101B1 (es) |
| JP (4) | JP6157461B2 (es) |
| KR (1) | KR20140058532A (es) |
| CN (2) | CN103796681B (es) |
| AU (3) | AU2012275133B2 (es) |
| BR (1) | BR112013033661A2 (es) |
| CA (1) | CA2839462A1 (es) |
| CL (1) | CL2013003725A1 (es) |
| CO (1) | CO6841996A2 (es) |
| CR (1) | CR20130661A (es) |
| DK (2) | DK2726101T3 (es) |
| DO (1) | DOP2013000313A (es) |
| ES (2) | ES2694749T3 (es) |
| GT (1) | GT201300323A (es) |
| HR (1) | HRP20181786T1 (es) |
| HU (1) | HUE040455T2 (es) |
| LT (1) | LT2726101T (es) |
| MA (1) | MA35280B1 (es) |
| MX (1) | MX354922B (es) |
| MY (1) | MY180616A (es) |
| NI (1) | NI201300140A (es) |
| PE (1) | PE20141469A1 (es) |
| PH (1) | PH12013502684A1 (es) |
| PL (2) | PL3357511T3 (es) |
| PT (2) | PT2726101T (es) |
| RS (1) | RS57996B1 (es) |
| RU (1) | RU2657440C2 (es) |
| SG (1) | SG10201604715VA (es) |
| SI (1) | SI2726101T1 (es) |
| TN (1) | TN2013000532A1 (es) |
| UA (1) | UA116191C2 (es) |
| WO (1) | WO2013003761A1 (es) |
| ZA (1) | ZA201309532B (es) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3434767T (pt) | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| CN103796681B (zh) | 2011-06-30 | 2018-07-20 | 建新公司 | T细胞活化的抑制剂 |
| US8956619B2 (en) * | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| CA2894511C (en) | 2012-12-11 | 2021-12-07 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for high throughput receptor:ligand identification |
| GB201311487D0 (en) * | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| AU2015244814B2 (en) | 2014-04-07 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
| MX2016014434A (es) * | 2014-05-13 | 2017-02-23 | Chugai Pharmaceutical Co Ltd | Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion. |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| CN116059378A (zh) | 2014-12-10 | 2023-05-05 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
| CN104459129A (zh) * | 2015-01-05 | 2015-03-25 | 复旦大学附属华山医院 | 一种鉴别活动性与潜伏性结核分枝杆菌感染的诊断试剂盒 |
| CN121159719A (zh) | 2015-04-17 | 2025-12-19 | 高山免疫科学股份有限公司 | 具有可调的亲和力的免疫调节蛋白 |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| HUE068868T2 (hu) | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| CN108513576A (zh) * | 2015-09-14 | 2018-09-07 | 高山免疫科学股份有限公司 | 可调变体免疫球蛋白超家族结构域和工程改造的细胞治疗 |
| US10273281B2 (en) | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| WO2017086419A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
| WO2017086367A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| IL260021B (en) | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| KR101918456B1 (ko) * | 2015-12-15 | 2018-11-16 | 앱클론(주) | Cd80 및 cd86에 특이적으로 결합하는 항체 |
| US11045547B2 (en) | 2015-12-16 | 2021-06-29 | Merck Sharp & Dohme Corp. | Anti-LAG3 antibodies and antigen-binding fragments |
| EP3192805A1 (en) | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
| WO2017151818A2 (en) * | 2016-03-02 | 2017-09-08 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3443123B1 (en) * | 2016-04-11 | 2021-08-11 | Board of Regents, The University of Texas System | Methods and compositions for detecting single t cell receptor affinity and sequence |
| WO2017181152A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| MX2018012472A (es) | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
| CN109689096A (zh) | 2016-05-18 | 2019-04-26 | 阿尔伯特爱因斯坦医学院公司 | 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法 |
| WO2017201210A1 (en) | 2016-05-18 | 2017-11-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| ES2973548T3 (es) | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF |
| US20200010528A1 (en) | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| SG11201907769XA (en) | 2017-03-16 | 2019-09-27 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| KR20190141146A (ko) | 2017-03-16 | 2019-12-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Pd-l2 변이체 면역조절 단백질 및 그의 용도 |
| KR20190139216A (ko) | 2017-04-28 | 2019-12-17 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법 |
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| BR112020007542A2 (pt) | 2017-10-18 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados |
| CA3083748A1 (en) * | 2017-11-29 | 2019-06-06 | Uti Limited Partnership | Methods of treating autoimmune disease |
| CN108003238B (zh) * | 2017-11-30 | 2021-02-02 | 常州费洛斯药业科技有限公司 | 一种能特异识别ctla-4的全人源单克隆抗体或抗体片段及其方法和用途 |
| AU2019205273B2 (en) | 2018-01-03 | 2024-04-04 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| CN111886241A (zh) | 2018-01-09 | 2020-11-03 | 库尔生物制药有限公司 | 多聚体t细胞调节多肽及其使用方法 |
| EP3747456A4 (en) * | 2018-01-31 | 2021-12-01 | Tohoku University | PROCESS FOR REGULATING THE EXPRESSION OF THE SPECIFIC MHC OF AN ANTIGEN |
| KR20210010896A (ko) * | 2018-05-14 | 2021-01-28 | 이뮤노코어 리미티드 | 이기능성 결합 폴리펩타이드 |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| CA3120868A1 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| US12589132B2 (en) | 2019-02-22 | 2026-03-31 | Five Prime Therapeutics, Inc. | CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors |
| AU2020389422B2 (en) * | 2019-11-20 | 2024-08-08 | Gi Cell, Inc. | Medium composition for culturing T cells and method for culturing T cells using same |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| CN114805591A (zh) * | 2022-03-31 | 2022-07-29 | 浙江大学 | 靶向ctla-4及配体cd80或cd86的双特异性抗体、筛选方法、组合物及应用 |
| EP4569332A1 (en) * | 2022-08-12 | 2025-06-18 | Abata Therapeutics, Inc. | Stable regulatory t cells and methods of production |
| CN118240024A (zh) * | 2024-03-19 | 2024-06-25 | 江苏省原子医学研究所 | 一种靶向fgl1的多肽及其应用 |
| WO2025242209A1 (zh) * | 2024-05-24 | 2025-11-27 | 杭州阿诺生物医药科技有限公司 | 一种融合多肽及其用途 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5149782A (en) | 1988-08-19 | 1992-09-22 | Tanox Biosystems, Inc. | Molecular conjugates containing cell membrane-blending agents |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| UA71889C2 (uk) | 1996-04-02 | 2005-01-17 | Йєда Рісерч Енд Дівелопмент Ко. Лтд. | Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування |
| IL130123A (en) | 1996-11-28 | 2007-07-24 | Roussy Inst Gustave | LAG-3 protein mutants, their expression, use and method of production |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| EP1599502A1 (en) * | 2003-02-27 | 2005-11-30 | TheraVision GmbH | A molecule which binds cd80 and cd86 |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| PL1897548T5 (pl) | 2003-02-28 | 2025-03-17 | The Johns Hopkins University | Regulacja komórek T |
| CA2566473A1 (en) | 2004-05-17 | 2005-12-08 | Board Of Trustees Of The University Of Illinois | Uses of bispecific antibody (biab) coated dendritic cells pulsed with antigens |
| US20090252741A1 (en) * | 2004-09-08 | 2009-10-08 | Ohio State University Research Foundation | Human monoclonal anti-ctla4 antibodies in cancer treatment |
| PT2229956E (pt) * | 2004-09-13 | 2013-07-31 | Genzyme Corp | Contruções multiméricas |
| WO2006078161A1 (en) | 2005-01-24 | 2006-07-27 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
| WO2008073160A2 (en) * | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
| WO2008157367A1 (en) | 2007-06-15 | 2008-12-24 | Genzyme Corporation | Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor |
| WO2009100140A1 (en) * | 2008-02-04 | 2009-08-13 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| EP2653545A1 (en) | 2008-02-05 | 2013-10-23 | Bicycle Therapeutics Limited | Methods and compositions |
| CN101951925A (zh) * | 2008-02-20 | 2011-01-19 | 建新公司 | 血管发生抑制 |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
| CN103796681B (zh) * | 2011-06-30 | 2018-07-20 | 建新公司 | T细胞活化的抑制剂 |
-
2012
- 2012-06-29 CN CN201280042085.9A patent/CN103796681B/zh active Active
- 2012-06-29 JP JP2014519165A patent/JP6157461B2/ja active Active
- 2012-06-29 EP EP12804528.3A patent/EP2726101B1/en active Active
- 2012-06-29 PH PH1/2013/502684A patent/PH12013502684A1/en unknown
- 2012-06-29 PL PL18151718T patent/PL3357511T3/pl unknown
- 2012-06-29 PE PE2013002910A patent/PE20141469A1/es active IP Right Grant
- 2012-06-29 KR KR1020147002646A patent/KR20140058532A/ko not_active Ceased
- 2012-06-29 PT PT12804528T patent/PT2726101T/pt unknown
- 2012-06-29 SI SI201231438T patent/SI2726101T1/sl unknown
- 2012-06-29 ES ES12804528.3T patent/ES2694749T3/es active Active
- 2012-06-29 HR HRP20181786TT patent/HRP20181786T1/hr unknown
- 2012-06-29 HU HUE12804528A patent/HUE040455T2/hu unknown
- 2012-06-29 MX MX2013015384A patent/MX354922B/es active IP Right Grant
- 2012-06-29 UA UAA201400833A patent/UA116191C2/uk unknown
- 2012-06-29 RS RS20181350A patent/RS57996B1/sr unknown
- 2012-06-29 PL PL12804528T patent/PL2726101T3/pl unknown
- 2012-06-29 PT PT181517186T patent/PT3357511T/pt unknown
- 2012-06-29 LT LTEP12804528.3T patent/LT2726101T/lt unknown
- 2012-06-29 BR BR112013033661A patent/BR112013033661A2/pt not_active Application Discontinuation
- 2012-06-29 EP EP18151718.6A patent/EP3357511B1/en active Active
- 2012-06-29 DK DK12804528.3T patent/DK2726101T3/en active
- 2012-06-29 CN CN201711283703.XA patent/CN107988156B/zh active Active
- 2012-06-29 WO PCT/US2012/045017 patent/WO2013003761A1/en not_active Ceased
- 2012-06-29 ES ES18151718T patent/ES2810424T3/es active Active
- 2012-06-29 CA CA2839462A patent/CA2839462A1/en not_active Abandoned
- 2012-06-29 MY MYPI2013004609A patent/MY180616A/en unknown
- 2012-06-29 RU RU2014102956A patent/RU2657440C2/ru not_active IP Right Cessation
- 2012-06-29 SG SG10201604715VA patent/SG10201604715VA/en unknown
- 2012-06-29 US US14/128,461 patent/US9834604B2/en active Active
- 2012-06-29 DK DK18151718.6T patent/DK3357511T3/da active
- 2012-06-29 AU AU2012275133A patent/AU2012275133B2/en not_active Ceased
-
2013
- 2013-12-13 CR CR20130661A patent/CR20130661A/es unknown
- 2013-12-18 ZA ZA2013/09532A patent/ZA201309532B/en unknown
- 2013-12-19 NI NI201300140A patent/NI201300140A/es unknown
- 2013-12-26 DO DO2013000313A patent/DOP2013000313A/es unknown
- 2013-12-26 CL CL2013003725A patent/CL2013003725A1/es unknown
- 2013-12-26 TN TNP2013000532A patent/TN2013000532A1/fr unknown
- 2013-12-26 GT GT201300323A patent/GT201300323A/es unknown
- 2013-12-27 CO CO13301377A patent/CO6841996A2/es unknown
-
2014
- 2014-01-22 MA MA36702A patent/MA35280B1/fr unknown
-
2017
- 2017-03-08 JP JP2017043440A patent/JP6530436B2/ja active Active
- 2017-10-19 US US15/788,433 patent/US11028170B2/en active Active
- 2017-11-15 AU AU2017261541A patent/AU2017261541B2/en not_active Ceased
-
2019
- 2019-05-15 JP JP2019091790A patent/JP6826154B2/ja active Active
- 2019-09-09 AU AU2019226276A patent/AU2019226276B2/en not_active Expired - Fee Related
-
2021
- 2021-01-14 JP JP2021003877A patent/JP2021073216A/ja active Pending
- 2021-05-03 US US17/306,509 patent/US12043665B2/en active Active
-
2024
- 2024-06-12 US US18/741,190 patent/US20250002578A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141469A1 (es) | Inhibidores de la activacion de las celulas t | |
| MX2015011731A (es) | Inhibidores macrociclicos de las interacciones proteina/proteina de proteina de muerte programada 1 (pd-1) /ligando de muerte programada 1 (pd-l1) y cumulo de diferenciacion 80 (b7-1) cd80 (b7-1) /ligando de muerte programada 1 (pd-l1). | |
| CO2017003077A2 (es) | Inhibidores macrocíclicos de las interacciones proteína/proteína de muerte programada 1 (pd-1)/pd-l1 y cd80(b7-1)/pd-l1 | |
| CL2017000855A1 (es) | Inmunomoduladores | |
| CO2018010316A2 (es) | Inmunomoduladores | |
| MX2016013963A (es) | Metodos mejorados para la elaboracion de terapias celulares adoptivas. | |
| UY37194A (es) | Inmunomoduladores | |
| CO2018001149A2 (es) | Anticuerpos monoclonales contra bcma | |
| PE20142407A1 (es) | Formulacion de anticuerpos | |
| AR105053A1 (es) | Inmunomoduladores | |
| CL2018000750A1 (es) | Método de redireccionamiento de linfocitos t para el tratamiento de la infección por vih | |
| AR072571A1 (es) | Composiciones monovalentes para union a cd28 y procedimientos de uso | |
| MX2017006408A (es) | Linfocitos t gamma delta modificados geneticamente. | |
| CL2014001963A1 (es) | Anticuerpo contra la molecula de guia repulsiva (rgma); composición que la comprende y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas. | |
| MX2015012920A (es) | Celulas presentadoras de antígeno artificial de nanoescala. | |
| EA201291019A1 (ru) | Применение сильной сдвиговой деформации в доставке лекарственных средств | |
| AR111752A1 (es) | Anticuerpos agonistas contra el atenuador de linfocitos b y t (btla) y sus usos | |
| BR112017006520A2 (pt) | métodos de tratamento do lúpus eritematoso sistêmico usando um anticorpo de domínio direcionado contra cd28 | |
| MX2017003903A (es) | Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. | |
| UY35733A (es) | Inhibidores macrocíclicos de las interacciones proteína/proteína pd-1/pd-l1 y cd80(b7-1)/pd-l1 i.p.c. | |
| MX371137B (es) | Receptor fc gama humano soluble. | |
| AR095638A1 (es) | Método y sistema para transferir configuraciones de un usuario a otro dispositivo receptor del usuario | |
| AR095488A1 (es) | Inhibidores macrocíclicos de las interacciones proteína/proteína pd-1/pd-l1 y cd80(b7-1)/pd-l1 | |
| CL2017000601A1 (es) | Inhibidores macrocíclicos de las interacciones proteína/proteína de muerte programada 1 (pd-1)/pd-l1 y cd80(b7-1)/pd-l1 | |
| TH158861A (th) | ตัวยับยั้งการกระตุ้นทีเซลล์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |